VR Adviser’s Cogent Biosciences COGT Stock Holding History

VR Adviser’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.6M	Sell	1,642,166 -357,834	-18%	-$12.5M	1.93%	10
2026 Q1	$77M	Hold	2,000,000	–	–	2.87%	9
2025 Q4	$71M	Sell	2,000,000 -2,000,000	-50%	-$56.2M	3.51%	8
2025 Q3	$57.4M	Sell	4,000,000 -755,411	-16%	-$8.95M	3.23%	10
2025 Q2	$34.1M	Sell	4,755,411 -929,000	-16%	-$5.15M	2.56%	11
2025 Q1	$34M	Hold	5,684,411	–	–	2.9%	11
2024 Q4	$44.3M	Buy	5,684,411 +244	+0%	+$2.43K	3.04%	11
2024 Q3	$61.4M	Hold	5,684,167	–	–	3.22%	11
2024 Q2	$47.9M	Buy	5,684,167 +555,000	+11%	+$4.21M	3.05%	12
2024 Q1	$34.5M	Buy	5,129,167 +445,000	+10%	+$2.75M	1.64%	19
2023 Q4	$27.5M	Hold	4,684,167	–	–	1.89%	16
2023 Q3	$45.7M	Buy	4,684,167 +35	+0%	+$415	4.81%	4
2023 Q2	$55.5M	Sell	4,684,132 -200,845	-4%	-$2.3M	8.87%	2
2023 Q1	$52.7M	Buy	4,884,977 +846,860	+21%	+$10.8M	10.29%	2
2022 Q4	$46.7M	Hold	4,038,117	–	–	7.86%	4
2022 Q3	$60.2M	Hold	4,038,117	–	–	9.3%	3
2022 Q2	$36.4M	Buy	4,038,117 +2,949,300	+271%	+$20.1M	7.17%	5
2022 Q1	$8.15M	Hold	1,088,817	–	–	1.32%	19
2021 Q4	$9.34M	Hold	1,088,817	–	–	1.28%	20
2021 Q3	$9.16M	Hold	1,088,817	–	–	1.18%	21
2021 Q2	$8.83M	Hold	1,088,817	–	–	1.07%	23
2021 Q1	$9.56M	Hold	1,088,817	–	–	1.04%	21
2020 Q4	$12.2M	Sell	1,088,817 -1	-0%	-$11	1.8%	16
2020 Q3	$10.2M	Buy	+1,088,818	New	+$11.4M	1.99%	16

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VR Adviser's COGT Position: Q2 2026 in Review

VR Adviser reduced its Cogent Biosciences (COGT) stake by 18% in Q2 2026, selling an estimated $12.5M and leaving 1,642,166 shares worth $63.6M. The position accounts for 1.93% of the portfolio, ranked #10.

VR Adviser first reported a position in COGT in Q3 2020 and has held it in 24 quarters since. The position peaked at $77M in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

VR Adviser held 1,642,166 shares of Cogent Biosciences worth $63.6M as of Q2 2026.
VR Adviser sold 357,834 Cogent Biosciences shares in Q2 2026, an estimated $12.5M.
Cogent Biosciences made up 1.93% of VR Adviser's portfolio in Q2 2026, its #10 holding.
VR Adviser first reported a position in Cogent Biosciences in Q3 2020 and has held it in 24 quarters since.
VR Adviser's Cogent Biosciences position peaked at $77M in Q1 2026.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.